ArticleJournal of thoracic disease2025
Circulating tumor DNA in lung cancer: a bibliometric analysis of studies published from 2001 to 2024.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the most prevalent cancer worldwide, yet challenges persist in early diagnosis, prediction of therapeutic effect, treatment monitoring, and prognosis. Circulating tumor DNA (ctDNA) has garnered heightened research attention as a noninvasive biomarker of lung cancer. However, the literature on ctDNA in lung cancer has not been extensively characterized. Therefore, a bibliometric analysis of studies on ctDNA and lung cancer was conducted to address this deficiency. Methods: Publications on ctDNA and lung cancer published from 2001 to 2024 were collected from the Web of Science Core Collection (WoSCC). CiteSpace, VOSviewer, and Bibliometrix software were used to visualize the status and future trends of the research in this field. Results: A total of 978 publications from 6,656 authors and 58 countries/regions were retrieved. The analysis indicated a steadily rising trend in publication volume from 2015 onward. China had the highest number of publications, and the United States had the highest centrality; meanwhile, the University of Texas MD Anderson Cancer Center had the highest centrality among organizations. Centrality/productivity and collaborations among countries/regions, institutions, journals, and authors were visualized. Residual disease, adjuvant chemotherapy, outcome prediction, immunotherapy, programmed cell death ligand-1 (PD-L1) expression, pembrolizumab, efficacy, recurrence, and risk are the current research frontiers in this field. Conclusions: Results from the bibliometric analysis provide a global perspective and intuitive understanding of this field, emphasizing the application value of ctDNA in lung cancer diagnosis, prognosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.